Dr. Jeyarajah on SIR-Spheres® Y-90 Resin Microspheres as Maintenance in CRC With Liver Metastases

Video

Rohan Jeyarajah, MD, discusses the potential role of SIR-Spheres® Y-90 resin microspheres from Sirtex Medical in colorectal cancer with liver metastases.

Rohan Jeyarajah, MD, hepatopancreaticobiliary surgeon, Methodist Richardson Medical Center, discusses the potential role of SIR-Spheres® Y-90 resin microspheres from Sirtex Medical in colorectal cancer (CRC) with liver metastases.

Although the data with maintenance therapy in CRC with liver metastases are inconclusive, the general goal of maintenance treatment is to de-escalate chemotherapy, Jeyarajah explains. For example, a patient could receive full-dose FOLFOX chemotherapy for 12 cycles but de-escalate to 5-fluorouracil plus a biologic agent in the maintenance setting if they have small volume disease to optimize quality of life (QOL).

Y-90 resin may be utilized in patients with liver-predominant disease to further improve QOL and eliminate the need for chemotherapy completely in the maintenance setting, Jeyarajah says. However, if patients have other sites of disease like lung metastases or retroperitoneal lymphadenopathy, chemotherapy should be continued as maintenance.

Ultimately, Y-90 resin may have a role as maintenance therapy in patients with liver-predominant disease to control liver disease with minimal toxicity, Jeyarajah concludes.

Related Videos
Jeremy M. Pantin, MD, clinical director, Adult Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, bone marrow transplant physician, Sarah Cannon Research Institute
Maria Hafez, MD, assistant professor, breast and sarcoma medical oncologist, director, Clinical Breast Cancer Research, Sidney Kimmel Medical College, Thomas Jefferson University
Zeynep Eroglu, MD
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Akriti Jain, MD
Raj Singh, MD
Gottfried Konecny, MD
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Ramez N. Eskander, MD